Lifeward (LFWD) to Announce Quarterly Earnings on Friday

Lifeward (NASDAQ:LFWD) is expected to be announcing its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to post earnings of ($1.3862) per share and revenue of $6.5310 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Lifeward (NASDAQ:LFWD) last announced its quarterly earnings results on Friday, May 15th. The company reported ($6.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52). Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%. The company had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $5.78 million. On average, analysts expect Lifeward to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lifeward Stock Down 1.6%

LFWD opened at $7.58 on Wednesday. The company has a quick ratio of 1.82, a current ratio of 2.40 and a debt-to-equity ratio of 1.16. The firm has a 50 day moving average price of $7.40 and a 200-day moving average price of $7.00. Lifeward has a twelve month low of $4.14 and a twelve month high of $10.56. The stock has a market capitalization of $21.47 million, a price-to-earnings ratio of -0.39 and a beta of 0.38.

Analyst Ratings Changes

LFWD has been the topic of several research reports. Weiss Ratings upgraded shares of Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 3rd. Zacks Research raised Lifeward from a “strong sell” rating to a “hold” rating in a report on Monday, July 27th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Lifeward presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Lifeward

A number of institutional investors and hedge funds have recently made changes to their positions in the business. HRT Financial LP grew its position in Lifeward by 149.7% during the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after buying an additional 29,423 shares during the period. Virtu Financial LLC raised its position in Lifeward by 158.0% in the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after acquiring an additional 37,037 shares during the period. Jane Street Group LLC boosted its stake in shares of Lifeward by 77.3% during the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after acquiring an additional 29,927 shares during the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of Lifeward by 1,271.8% during the 3rd quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after acquiring an additional 198,406 shares during the last quarter. Hedge funds and other institutional investors own 26.76% of the company’s stock.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.